Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

ConclusionsThese findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years.

http://rd.springer.com/10.1007/s40121-024-00939-w

Source: Infectious Diseases and Therapy - March 20, 2024 Category: Infectious Diseases Source Type: research